16 July 2023: Clinical Research
A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
Hanzhao Yang CDE , Yadong Sun BCD , Peili Wang BD , Jianghua Qiao BC , Lianfang Li B , Zhenduo Lu B , Xianfu Sun B , Chongjian Zhang B , Xiuchun Chen B , Min Yan B , Shude Cui B , Chengzheng Wang ADF , Zhenzhen Liu AE*DOI: 10.12659/MSM.940124
Med Sci Monit 2023; 29:e940124
Table 2 Univariable and multivariable analysis among HR+/HER2− patients.
| Characteristics | pN1 (n=367) | pN2-3 (n=77) | Univariable P | Multivariable P |
|---|---|---|---|---|
| Age, no. (%) | 0.747 | |||
| 179 (48.8) | 36 (46.8) | |||
| ≥50 | 188 (51.2) | 41 (53.2) | ||
| Menopausal status, no. (%) | 0.990 | |||
| Absent | 210 (57.2) | 44 (57.1) | ||
| Present | 157 (42.8) | 33 (42.9) | ||
| Multifocality, no. (%) | 0.356 | |||
| Absent | 328 (89.4) | 66 (85.7) | ||
| Present | 39 (10.6) | 11 (14.3) | ||
| Clinical tumor stage, no. (%) | 0.001 | |||
| 1 | 241 (65.7) | 33 (42.9) | ||
| 2 | 126 (34.3) | 44 (57.1) | ||
| US-ALN, no. (%) | 0.003 | |||
| Normal | 260 (70.8) | 38 (49.4) | ||
| Abnormal | 107 (29.2) | 39 (50.6) | ||
| Mammographic calcifications | 0.017 | 0.006 | ||
| Absent | 309 (84.2) | 56 (72.7) | ||
| Present | 58 (15.8) | 21 (27.3) | ||
| Surgery, no. (%) | 0.602 | |||
| Mastectomy | 291 (79.3) | 59 (76.6) | ||
| Breast-conserving | 76 (20.7) | 18 (23.4) | ||
| Tumor type, no. (%) | 0.571 | |||
| Ductal | 353 (96.1) | 72 (93.5) | ||
| Lobular | 11 (3.0) | 4 (5.2) | ||
| Others | 3 (0.9) | 1 (1.3) | ||
| Histological grade, no. (%) | 0.880 | |||
| I | 6 (1.6) | 1 (1.3) | ||
| II | 329 (89.6) | 68 (88.3) | ||
| Missing | 32 (8.8) | 8 (10.4) | ||
| No. positive SLNs removed | ||||
| 1 | 287 (78.2) | 31 (40.2) | ||
| 2 | 80 (21.8) | 46 (59.8) | ||
| No. negetive SLNs removed | 0.004 | |||
| 0 | 18 (4.9) | 10 (13.0) | ||
| 1 | 66 (18.0) | 18 (23.4) | ||
| 2 | 79 (21.5) | 9 (11.7) | ||
| 3 | 65 (17.7) | 20 (26.0) | ||
| ≥4 | 139 (37.9) | 20 (26.0) | ||
| LVI, no. (%) | 0.420 | |||
| Absent | 285 (77.7) | 63 (81.8) | ||
| Present | 82 (22.3) | 14 (18.2) | ||
| Progesterone receptor | 0.895 | |||
| Negative | 27 (7.4) | 6 (7.8) | ||
| Positive | 340 (92.6) | 71 (92.2) | ||
| HER-2, no. (%) | 0.151 | |||
| 0 | 48 (13.1) | 16 (20.8) | ||
| 1 | 112 (30.5) | 25 (32.5) | ||
| 2 | 207 (56.4) | 36 (46.7) | ||
| US-ALN – ultrasound finding axillary lymph node; SLN – sentinel lymph node; LVI – lymphovascular invasion. | ||||